TY - JOUR
T1 - Docetaxel resistance in prostate cancer
T2 - Taking it up a notch
AU - Zhang, Tian
AU - Armstrong, Andrew J.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
AB - Notch signaling is implicated in prostate cancer progression and docetaxel resistance. Cui and colleagues describe the additive efficacy and mechanisms of a γ-secretase inhibitor, PF-03084014, and docetaxel in preclinical models of prostate cancer, suggesting the need for further clinical development of Notch pathway modulators in men with metastatic prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=84945541343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945541343&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1613
DO - 10.1158/1078-0432.CCR-15-1613
M3 - Article
C2 - 26307134
AN - SCOPUS:84945541343
SN - 1078-0432
VL - 21
SP - 4505
EP - 4507
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 20
ER -